Data · dataset · 2026
<p>Clinical outcomes according to type 1 and type 2 mutations.</p>
Listed in UCL Research Data Repository
<p>A. Circos plot of 21 genetic mutations detected in this study.
Description
Genes are classified into three categories according to the outer arc colors: green indicates Type 1 mutations, purple indicates Type 2 mutations, and blue indicates other mutations. Ribbons connecting genes represent pairwise associations between mutations.
Red ribbons indicate positive associations, whereas blue ribbons indicate negative associations; color intensity reflects the statistical significance of the association, expressed as −log10(P value). B. The distribution of gene mutations: type 1 mutations only, 34%; type 2 mutations only, 23%; neither type 1 nor type 2 mutations, 26%; and both types, 17%. C. Response rates according to gene groups: type 1+ and type 2- (CR/CRi 72%, non-CR 28%), type 1- and type 2+ (CR/CRi 33%, non-CR 67%).
Read the rest (3 more)
D. A representative case of type 1 mutation only (#HM02–138): An AML patient harbored <i>FLT3-ITD</i> (Q580_Y597dup, Y589_F590ins11), <i>NRAS</i> G13D, and <i>PTPN11</i> P491L mutations. The patient received Aza/Ven and achieved CRi, followed by allogeneic stem cell transplantation (allo-SCT). Although the patient relapsed after allo-SCT, two additional cycles of Aza/Ven induced a second remission.
E. Response rates according to gene groups: type 1- and type 2- (CR/CRi 57%, non-CR 43%), type 1+ and type 2+ (CR/CRi 44%, non-CR 56%). F. Overall survival (OS) according to gene groups: type 1+ and type 2-; median OS 16.4 months (95% CI: 5.3-NA), type 1- and type 2 + ; median OS 4.9 months (95% CI: 1.2-NA), type 1+ and type 2 + ; median OS 10.2 months (95% CI: 2.2-NA), type 1- and type 2-; median OS 14.5 months (95% CI: 3.9–23.1) (p = 0.0303).
OS differed significantly between the type 1 + /type 2 − group and the type 1 − /type 2 + group (p = 0.0023). Aza, azacitidine; CI, confidence interval; CR, complete remission; CRi, CR with incomplete hematologic recovery; Dx, diagnosis; OS, overall survival; NA, not available; Rel, relapse; SCT, stem cell transplantation; Ven, venetoclax.</p>
Links
Where it is published
- DOI doi.org/10.1371/journal.pone.0357898.g003 ↗
DOI / persistent id · from rdr ucl ac uk
Catalogue records · 1
- OAI-PMH record api.figshare.com/v2/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Af… ↗
metadata API · from rdr ucl ac uk
Topics
- From keywords
- Cancer · Earth & Environmental Science · Genetics · Life Sciences · Medicine & Health · Plant biology
Provenance · 1 source records, 11 field assertions
| Source | Key | Last seen | Raw |
|---|---|---|---|
| UCL Research Data Repository | oai:figshare.com:article/34050066 | 13 d ago | JSON v1 |
| Field | Assertion | Extractor | Evidence |
|---|---|---|---|
| access_level | source · rdr ucl ac uk | connector:rdr_ucl_ac_uk@1.0.0 | |
| concepts[disease].local:disease:cancer | mapping · rdr ucl ac uk | vocabulary-mapper@1.0.0 | keywords['Cancer'] |
| concepts[field].anzsrc:group:3105 | mapping · rdr ucl ac uk | vocabulary-mapper@1.0.0 | keywords['Genetics'] |
| concepts[field].anzsrc:group:3108 | mapping · rdr ucl ac uk | vocabulary-mapper@1.0.0 | keywords['Plant Biology'] |
| concepts[field].local:field:earth-environmental | mapping · rdr ucl ac uk | connector:rdr_ucl_ac_uk@1.0.0 | |
| concepts[field].local:field:life-sciences | mapping · rdr ucl ac uk | connector:rdr_ucl_ac_uk@1.0.0 | |
| concepts[field].local:field:medicine-health | mapping · rdr ucl ac uk | connector:rdr_ucl_ac_uk@1.0.0 | |
| description | source · rdr ucl ac uk | connector:rdr_ucl_ac_uk@1.0.0 | /metadata/dc/description |
| license | source · rdr ucl ac uk | connector:rdr_ucl_ac_uk@1.0.0 | /metadata/dc/rights |
| publication_date | source · rdr ucl ac uk | connector:rdr_ucl_ac_uk@1.0.0 | |
| title | source · rdr ucl ac uk | connector:rdr_ucl_ac_uk@1.0.0 | /metadata/dc/title |